GLOW

Glow peptide in Canada is supplied by Horizon Peptides as a lyophilized three-component research blend in a sealed vial, available singly or in 3-vial and 10-vial packs. Glow combines BPC-157, TB-500 and GHK-Cu, pairing two tissue-signalling sequences with a copper-binding tripeptide.

Glow is a fixed combination rather than a single compound. Each formulation consists of 10 mg BPC-157, 10 mg TB-500 and 70 mg GHK-Cu, with the copper tripeptide making up the large majority of the material by mass.

That weighting is what distinguishes Glow from the catalogue’s other blends. Where a four-part combination spreads its mass across more sequences, Glow is built around GHK-Cu and uses the two shorter tissue-signalling peptides as secondary components, which makes it a common choice for copper-peptide research models that also call for those sequences.

Because the three sequences are supplied together in fixed proportion, the blend is most often used where a study calls for all three present at once, rather than where one is being isolated. Laboratories examining a single component usually work from that peptide’s own vial instead.

Each peptide in the blend is also stocked separately: BPC-157, TB-500 and GHK-Cu. The four-component Klow blend adds KPV to the same base, and the formulation is also offered as the Glow nasal spray and the Glow pre-mixed pen.